Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P130005/S048

Diamondback 360 Coronary Orbital Atherectomy System; Diamondback 360 Precision Coronary Orbital Atherectomy System

Cardiovascular Systems, Inc. · Decision date Jan 14, 2026

FDA DECISIONP130005/S048

What did the FDA approve?

FDA records P130005/S048 as a supplement to PMA P130005, with the supplement type “Special (Immediate Track)”. The recorded decision is approval, dated Jan 14, 2026.

FDA approval order statement

labeling updates to add IEC 60601 electrical safety warnings to the electronic Instructions for Use
Regulatory pathway
PMA supplement
Supplement type
Special (Immediate Track)
Clinical specialty
Cardiovascular
Decision date
Jan 14, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P130005/S048
Regulatory pathway
PMA supplement
Product code
MCX
Decision code
APPR
Decision date
Jan 14, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: CATHETER, CORONARY, ATHERECTOMY.

Product code
MCX
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P130005/S048 received

    Application receipt date recorded by FDA.

  2. P130005/S048 · FDA decision

    Special (Immediate Track)

  3. P130005/S049 · Related supplement

    DIAMONDBACK 360 CORONARY ORBITAL ATHERECTOMY SYSTEM

  4. P130005/S050 · Related supplement

    Diamondback 360 Coronary Orbital Atherectomy System; Diamondback 360 Precision Coronary Orbital Atherectomy System

  5. P130005/S051 · Related supplement

    Diamondback 360 Coronary Orbital Atherectomy System; Diamondback 360 Precision Coronary Orbital Atherectomy System

Timeline entries are records held by MedtechLedger for P130005. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P130005

Explore the linked device profile

Other records with product code MCX

Product / regulatory recordCompanyPathwayDecision dateSource
Boston Scientific CorpPMA supplementOct 21, 2026FDA
Boston Scientific CorpPMA supplementOct 21, 2026FDA
Boston Scientific CorpPMA supplementOct 20, 2026FDA
Boston Scientific CorpPMA supplementMay 6, 2026FDA
Boston Scientific CorpPMA supplementApr 9, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Cardiovascular Systems, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
651 Campus Dr., Minneapolis, MN, 55211

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records